Reconnect with nature

SWISS PRECISION DESIGN OF Next Generation Psychedelic Medicine

Reconnect Labs is a spin-off of the University of Zürich, with the mission to develop innovative, rapid-acting and sustainable therapies for affective disorders (anxiety, depression, trauma, addiction), and neurodegenerative diseases. It is specialized on the development of next generation psychedelic medicines with increased safety, tolerability and efficacy in mental health applications. Impact-driven, patient-centered, and rooted in evidence-based research and reciprocity, the hybrid organization consisting of Reconnect Labs and Reconnect Foundation is setting standards for ethical drug development companies.

Investor Contact